A Phase 2 interventional study of CINRYZE with rHuPH20 in Hereditary Angioedema, sponsored by Shire. Completed at 4 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2021-07-19.
Sponsored by Shire (part of Takeda) · Phase 2, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing C1 esterase inhibitor (human) in Angioedemas, Hereditary — 1 open to participants now, 1 under way, none of them phase 3. C1 esterase inhibitor (human) · Angioedemas, Hereditary.
Among the 11 studies testing C1 esterase inhibitor (human) in Angioedemas, Hereditary, this one is the 10th largest by enrollment, is the only one that started in 2011, is one of 8 in phase 2, and was the 7th registered.
171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.
Browse Angioedemas, Hereditary studies →1 of the 11 studies testing C1 esterase inhibitor (human) in Angioedemas, Hereditary is open now, in 1 country. Recruiting first, the newest first:
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18–75
By country, each count listing its studies:
C1 esterase inhibitor (human): first FDA approval 2008 (Cinryze), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 9 · Phase 3 2 · Phase 4 1
First in 2004; this study’s year is marked. 1 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12 is below the median of 48 across 116 interventional studies indexed under Angioedemas, Hereditary.
Median enrollment 32 across the 11 interventional studies. Of the 9 that completed or were terminated, 9 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 11 have an industry lead sponsor. The 4 most frequent:
This study is registered under Shire, one of the names counted as Takeda. Under that name alone:
Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.
58 studies in Angioedemas, Hereditary by Takeda: 3 open now, 4 under way, none of them phase 3. Of 52 finished, 33 (63%) have results posted.
Among the 58 studies in Angioedemas, Hereditary by Takeda, this one is the 27th largest by enrollment of the 36 interventional ones that give a count, is the only one that started in 2011, is one of 5 in phase 2, and was the 20th registered.
Takeda’s Angioedemas, Hereditary studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing C1 esterase inhibitor (human) in Angioedemas, Hereditary, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 58 in Angioedemas, Hereditary:
This tab as a report to print or save as PDF → With an account.
The objectives of the study are to:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
To be eligible for this protocol, a subject must:
Exclusion Criteria:
To be eligible for this protocol, a subject must not:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subcutaneous injection of 1000 Units of CINRYZE with 20,000 Units of rHuPH20 twice weekly for two weeks
Biological: CINRYZE with rHuPH20
Subcutaneous injection of 2000 Units of CINRYZE with 40,000 Units of rHuPH20 twice weekly for two weeks
Biological: CINRYZE with rHuPH20
Drug pages: C1 esterase inhibitor (human) · Hyaluronidase (human recombinant)
Also known as: C1 esterase inhibitor (human), Recombinant human hyaluronidase
Incidence and Severity of Adverse Events, Number of Participants With Local Injection Site Reactions, and Number of Participants Who Discontinue Study Drug or Withdraw From the Study
Time frame: 18 days
Mean Change C1 Inhibitor (C1INH)
Mean Change in Baseline in Observed Plasma Concentration of C1 Inhibitor (C1INH) Antigen. Baseline-corrected concentrations were derived by subtracting the observed pre-dose concentrations on Day 1 of each treatment period from each observed concentration.
Time frame: 18 days
Mean Change C4 Compliment
Mean Change in Baseline in Observed Plasma Concentration of C4 Compliment. Baseline-corrected concentrations were derived by subtracting the observed pre-dose concentrations on Day 1 of each treatment period from each observed concentration.
Time frame: 18 days
Number of Subjects With C1 INH Antibodies
Time frame: Day 1 (pre-dose), Day 18 (168 h post Dose 4), and 30 (±2) days after the last dose of study drug (Dose 4)
| Milestone | Subcutaneous (SC) CINRYZE With Recombinant Human Hyaluronidase ph20 (rHuPH20) Dose Level 1 | SC CINRYZE With rHuPH20 Dose Level 2 |
|---|---|---|
| Started | 6 | 6 |
| Completed | 6 | 6 |
| Not completed | 0 | 0 |
| participants | Subcutaneous (SC) CINRYZE With Recombinant Human Hyaluronidase ph20 (rHuPH20) Dose Level 1 | SC CINRYZE With rHuPH20 Dose Level 2 |
|---|---|---|
| Number of participants with adverse events | 6 | 5 |
| Number of participants with injection site reactions | 6 | 5 |
| Number of participants who discontinued study drug | 0 | 0 |
| Number of participants who withdrew from the study | 0 | 0 |
Mean Change in Baseline in Observed Plasma Concentration of C1 Inhibitor (C1INH) Antigen. Baseline-corrected concentrations were derived by subtracting the observed pre-dose concentrations on Day 1 of each treatment period from each observed concentration.
| g/L | Subcutaneous (SC) With Recombinant Human Hyaluronidase ph20 (rHuPH20) CYNRYZE Dose 1 | SC CINRYZE With rHuPH20 Dose Level 2 |
|---|---|---|
| 0 Hour (h) | 0.0248 ± 0.0565 | 0.00483 ± 0.00904 |
| 1 hour (h) post Dose 1 | 0.0273 ± 0.065 | 0.00383 ± 0.00417 |
| 2 h post Dose 1 | 0.0302 ± 0.0637 | 0.008 ± 0.0123 |
| 3 h post Dose 1 | 0.0275 ± 0.0602 | 0.0095 ± 0.00729 |
| 4 h post Dose 1 | 0.0382 ± 0.0652 | 0.011 ± 0.00537 |
| 6 h post Dose 1 | 0.0398 ± 0.0599 | 0.020 ± 0.00678 |
| 8 h post Dose 1 | 0.0455 ± 0.0624 | 0.031 ± 0.0154 |
| 24 h post Dose 1 | 0.0625 ± 0.0728 | 0.0612 ± 0.0212 |
| 48 h post Dose 1 | 0.0665 ± 0.0749 | 0.0603 ± 0.0213 |
| Pre-Dose 2 | 0.0243 ± 0.0234 | 0.0507 ± 0.0168 |
| 1 h post Dose 2 | 0.0387 ± 0.0749 | 0.00833 ± 0.00852 |
| 120 h post Dose 1 | 0.020 ± 0.00883 | 0.0388 ± 0.0132 |
| Pre-Dose 3 | 0.0288 ± 0.0644 | 0.00833 ± 0.0095 |
| 1 h post Dose 3 | 0.00217 ± 0.00271 | 0.004 ± 0.00405 |
| Pre-Dose 4 | 0.006 ± 0.0119 | 0.0128 ± 0.00854 |
| 1 h post Dose 4 | 0.0193 ± 0.012 | 0.033 ± 0.0196 |
| 2 h post Dose 4 | 0.0233 ± 0.0126 | 0.0377 ± 0.021 |
| 3 h post Dose 4 | 0.0238 ± 0.012 | 0.0333 ± 0.0163 |
| 4 h post Dose 4 | 0.0257 ± 0.0142 | 0.037 ± 0.0215 |
| 6 h post Dose 4 | 0.0298 ± 0.0124 | 0.039 ± 0.025 |
| 8 h post Dose 4 | 0.0354 ± 0.0118 | 0.0397 ± 0.0157 |
| 24 h post Dose 4 | 0.0347 ± 0.018 | 0.0623 ± 0.0207 |
| 48 h post Dose 4 | 0.0273 ± 0.0171 | 0.0562 ± 0.00906 |
| 72 h post Dose 4 | 0.0167 ± 0.0185 | 0.046 ± 0.0106 |
| 120 h post Dose 4 | 0.0165 ± 0.0214 | 0.0157 ± 0.00797 |
| 168 h post Dose 4 | 0.00933 ± 0.0201 | 0.0382 ± 0.0935 |
Mean Change in Baseline in Observed Plasma Concentration of C4 Compliment. Baseline-corrected concentrations were derived by subtracting the observed pre-dose concentrations on Day 1 of each treatment period from each observed concentration.
| mg/L | Subcutaneous (SC) With Recombinant Human Hyaluronidase ph20 (rHuPH20) CYNRYZE Dose 1 | SC CINRYZE With rHuPH20 Dose Level 2 |
|---|---|---|
| 0 Hour (h) | 9.00 ± 15.4 | 13.3 ± 14.4 |
| 1 hour (h) post Dose 1 | 11.0 ± 14.3 | 10.3 ± 21.4 |
| 2 h post Dose 1 | 11.3 ± 13.8 | 11.0 ± 18.7 |
| 3 h post Dose 1 | 10.2 ± 11.7 | 11.5 ± 17.6 |
| 4 h post Dose 1 | 11.5 ± 13.6 | 13.2 ± 16.8 |
| 6 h post Dose 1 | 15.7 ± 14.2 | 14.0 ± 18.1 |
| 8 h post Dose 1 | 16.3 ± 16.6 | 22.5 ± 29.1 |
| 24 h post Dose 1 | 25.0 ± 15.6 | 30.5 ± 19.5 |
| 48 h post Dose 1 | 37.4 ± 23.1 | 49.8 ± 24.3 |
| Pre-Dose 2 | 24.3 ± 14.5 | 53.3 ± 23.2 |
| 1 h post Dose 2 | 37.5 ± 21.6 | 53.2 ± 22.6 |
| 120 h post Dose 1 | 35.6 ± 22.6 | 70.8 ± 28.4 |
| Pre-Dose 3 | 29.0 ± 19.1 | 66.3 ± 47.0 |
| 1 h post Dose 3 | 32.5 ± 18.7 | 69.3 ± 50.5 |
| Pre-Dose 4 | 32.0 ± 18.4 | 62.5 ± 54.2 |
| 1 h post Dose 4 | 30.2 ± 18.8 | 57.3 ± 53.7 |
| 2 h post Dose 4 | 33.3 ± 24.5 | 59.7 ± 52.5 |
| 3 h post Dose 4 | 34.3 ± 17.9 | 53.3 ± 46.2 |
| 4 h post Dose 4 | 34.8 ± 22.9 | 63.3 ± 56.5 |
| 6 h post Dose 4 | 36.3 ± 21.6 | 59.7 ± 46.4 |
| 8 h post Dose 4 | 33.6 ± 20.3 | 56.5 ± 48.4 |
| 24 h post Dose 4 | 37.8 ± 23.0 | 64.7 ± 52.4 |
| 48 h post Dose 4 | 33.0 ± 22.4 | 65.7 ± 47.0 |
| 72 h post Dose 4 | 23.3 ± 20.6 | 72.2 ± 57.5 |
| 120 h post Dose 4 | 16.8 ± 15.5 | 58.7 ± 46.4 |
| 168 h post Dose 4 | 19.0 ± 18.4 | 44.8 ± 46.0 |
| Participants | Subcutaneous (SC) With Recombinant Human Hyaluronidase ph20 (rHuPH20) CYNRYZE Dose 1 | SC CINRYZE With rHuPH20 Dose Level 2 |
|---|---|---|
| Day 1 (pre-dose) | 0 | 0 |
| Day 18 (168 h post Dose 4) | 0 | 0 |
| 30 (±2) days after the last dose of study drug (Dose 4) | 0 | 0 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Subcutaneous (SC) CINRYZE With Recombinant Human Hyaluronidase ph20 (rHuPH20) Dose Level 1 | — | 0/6 (0%) | 6/6 (100%) |
| SC CINRYZE With rHuPH20 Dose Level 2 | — | 0/6 (0%) | 5/6 (83.3%) |
| Event | Subcutaneous (SC) CINRYZE With Recombinant Human Hyaluronidase ph20 (rHuPH20) Dose Level 1 | SC CINRYZE With rHuPH20 Dose Level 2 |
|---|---|---|
| Injection site erythemaGeneral disorders | 5/6 | 5/6 |
| Injection site painGeneral disorders | 4/6 | 1/6 |
| Injection site swellingGeneral disorders | 2/6 | 0/6 |
| Injection site hemorrhageGeneral disorders | 1/6 | 0/6 |
| Injection site indurationGeneral disorders | 0/6 | 1/6 |
| Injection site edemaGeneral disorders | 1/6 | 0/6 |
| Injection site pruritusGeneral disorders | 1/6 | 0/6 |
| Upper respiratory tract infectionInfections and infestations | 1/6 | 0/6 |
| Urinary tract infectionInfections and infestations | 0/6 | 1/6 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/6 | 1/6 |
| Age, Continuous(years) | Subcutaneous (SC) CINRYZE With Recombinant Human Hyaluronidase ph20 (rHuPH20) Dose Level 1 | SC CINRYZE With rHuPH20 Dose Level 2 | Total |
|---|---|---|---|
| Mean | 31.5 ± 7.79 | 33.7 ± 10.27 | 32.6 ± 8.76 |
| Sex: Female, Male(Participants) | Subcutaneous (SC) CINRYZE With Recombinant Human Hyaluronidase ph20 (rHuPH20) Dose Level 1 | SC CINRYZE With rHuPH20 Dose Level 2 | Total |
|---|---|---|---|
| Female | 3 | 4 | 7 |
| Male | 3 | 2 | 5 |
Ran from Sep 2011 to primary completion in Nov 2011, 2 months.
Results were first posted in Jan 2013, 1 year 1 month after primary completion.
Of 17 phase 2 interventional studies under Angioedemas, Hereditary, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 35. This study's 2 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: C1 esterase inhibitor (human) · Hyaluronidase (human recombinant)